Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.03
ENDP's Cash to Debt is ranked lower than
97% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. ENDP: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
ENDP' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.66 Max: No Debt
Current: 0.03
Equity to Asset 0.31
ENDP's Equity to Asset is ranked lower than
87% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ENDP: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
ENDP' s Equity to Asset Range Over the Past 10 Years
Min: 0.08  Med: 0.52 Max: 0.76
Current: 0.31
0.08
0.76
F-Score: 2
Z-Score: 0.09
M-Score: -2.37
WACC vs ROIC
5.63%
-7.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -28.56
ENDP's Operating margin (%) is ranked lower than
84% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. ENDP: -28.56 )
Ranked among companies with meaningful Operating margin (%) only.
ENDP' s Operating margin (%) Range Over the Past 10 Years
Min: -31.17  Med: 20.88 Max: 30.74
Current: -28.56
-31.17
30.74
Net-margin (%) -45.74
ENDP's Net-margin (%) is ranked lower than
86% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. ENDP: -45.74 )
Ranked among companies with meaningful Net-margin (%) only.
ENDP' s Net-margin (%) Range Over the Past 10 Years
Min: -45.74  Med: 10.98 Max: 20.95
Current: -45.74
-45.74
20.95
ROE (%) -29.86
ENDP's ROE (%) is ranked lower than
83% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. ENDP: -29.86 )
Ranked among companies with meaningful ROE (%) only.
ENDP' s ROE (%) Range Over the Past 10 Years
Min: -85.73  Med: 12.36 Max: 20.94
Current: -29.86
-85.73
20.94
ROA (%) -9.12
ENDP's ROA (%) is ranked lower than
77% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. ENDP: -9.12 )
Ranked among companies with meaningful ROA (%) only.
ENDP' s ROA (%) Range Over the Past 10 Years
Min: -10.68  Med: 5.72 Max: 14.68
Current: -9.12
-10.68
14.68
ROC (Joel Greenblatt) (%) -69.36
ENDP's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. ENDP: -69.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENDP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -120.29  Med: 145.57 Max: 752.59
Current: -69.36
-120.29
752.59
Revenue Growth (3Y)(%) -14.10
ENDP's Revenue Growth (3Y)(%) is ranked lower than
87% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. ENDP: -14.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENDP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.1  Med: 20.30 Max: 30.3
Current: -14.1
-14.1
30.3
EBITDA Growth (3Y)(%) -2.90
ENDP's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. ENDP: -2.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ENDP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.9  Med: 19.80 Max: 75.9
Current: -2.9
-2.9
75.9
EPS Growth (3Y)(%) -36.70
ENDP's EPS Growth (3Y)(%) is ranked lower than
91% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. ENDP: -36.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ENDP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37  Med: 10.80 Max: 87.2
Current: -36.7
-37
87.2
» ENDP's 10-Y Financials

Financials (Next Earnings Date: 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ENDP Guru Trades in Q1 2015

Steve Mandel 3,270,117 sh (New)
Dodge & Cox 2,560 sh (New)
Louis Moore Bacon 38,262 sh (New)
Pioneer Investments 512,974 sh (+31.70%)
George Soros 2,217,176 sh (+26.79%)
John Griffin 4,939,000 sh (+12.02%)
RS Investment Management 356,720 sh (+1.36%)
Larry Robbins 6,845,883 sh (-0.08%)
Wallace Weitz 747,530 sh (-2.61%)
Mario Gabelli 14,650 sh (-26.38%)
» More
Q2 2015

ENDP Guru Trades in Q2 2015

Diamond Hill Capital 12,850 sh (New)
Kyle Bass 24,779 sh (New)
Paul Tudor Jones 50,589 sh (New)
Joel Greenblatt 11,516 sh (New)
Jim Simons 183,760 sh (New)
Louis Moore Bacon 685,413 sh (+1691.37%)
Larry Robbins 8,837,703 sh (+29.10%)
Wallace Weitz 961,135 sh (+28.57%)
Pioneer Investments 562,603 sh (+9.67%)
Steve Mandel 3,570,117 sh (+9.17%)
RS Investment Management 375,286 sh (+5.20%)
George Soros 2,299,781 sh (+3.73%)
Mario Gabelli 15,050 sh (+2.73%)
Dodge & Cox 2,560 sh (unchged)
John Griffin 4,200,000 sh (-14.96%)
» More
Q3 2015

ENDP Guru Trades in Q3 2015

Steven Cohen 400 sh (New)
John Paulson 1,710,000 sh (New)
Kyle Bass 52,634 sh (+112.41%)
Diamond Hill Capital 20,050 sh (+56.03%)
RS Investment Management 419,901 sh (+11.89%)
Mario Gabelli 16,350 sh (+8.64%)
Steve Mandel 3,859,641 sh (+8.11%)
Wallace Weitz 972,478 sh (+1.18%)
John Griffin 4,200,000 sh (unchged)
Jim Simons Sold Out
Dodge & Cox Sold Out
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 541,141 sh (-3.81%)
George Soros 2,016,984 sh (-12.30%)
Larry Robbins 6,944,273 sh (-21.42%)
Paul Tudor Jones 22,703 sh (-55.12%)
» More
Q4 2015

ENDP Guru Trades in Q4 2015

Louis Moore Bacon 20,751 sh (New)
Andreas Halvorsen 4,520,954 sh (New)
Steven Cohen 396,500 sh (+99025.00%)
John Paulson 3,302,200 sh (+93.11%)
RS Investment Management 543,593 sh (+29.46%)
George Soros 2,163,967 sh (+7.29%)
Kyle Bass Sold Out
Steve Mandel Sold Out
Larry Robbins Sold Out
Mario Gabelli 14,700 sh (-10.09%)
Wallace Weitz 684,923 sh (-29.57%)
Diamond Hill Capital 13,567 sh (-32.33%)
John Griffin 2,050,000 sh (-51.19%)
Pioneer Investments 229,122 sh (-57.66%)
Paul Tudor Jones 8,009 sh (-64.72%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Endo International PLC

Wallace Weitz Comments on Endo International - Apr 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain patch).

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Jan 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Endo International PLC

Wallace Weitz Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain Read more...
Wallace Weitz Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.
From Read more...
John Paulson Keeps Gold, Buys Drug Manufacturers in Q3 Investor increases health care bet as M&A activity abounds in sector
John Paulson (Trades, Portfolio) made billions in the housing crash and employs an event-driven arbitrage investing strategy at his firm Paulson & Co., where he manages about $19.5 billion. Outsized bets tend to make the manager’s returns vary to extremes. For instance, in recent years his funds lost as much as 36% for 2014, after gaining as much as 46% in 2013. Read more...
Dodge & Cox Buys 2 New Stocks
Dodge & Cox was founded in 1930 and is a firm employing a long-term approach and strict price discipline. It has $250 billion in assets under management and returned 11.32% on average annually over the past 20 years, compared to 9.39% for the S&P 500. Read more...

Ratios

vs
industry
vs
history
Forward P/E 4.12
ENDP's Forward P/E is ranked higher than
96% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. ENDP: 4.12 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.00
ENDP's P/B is ranked higher than
87% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. ENDP: 1.00 )
Ranked among companies with meaningful P/B only.
ENDP' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 2.77 Max: 17.5
Current: 1
0.98
17.5
P/S 1.59
ENDP's P/S is ranked higher than
68% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. ENDP: 1.59 )
Ranked among companies with meaningful P/S only.
ENDP' s P/S Range Over the Past 10 Years
Min: 1.05  Med: 2.70 Max: 6.1
Current: 1.59
1.05
6.1
POCF 91.53
ENDP's POCF is ranked lower than
90% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. ENDP: 91.53 )
Ranked among companies with meaningful POCF only.
ENDP' s POCF Range Over the Past 10 Years
Min: 4.02  Med: 9.88 Max: 212.54
Current: 91.53
4.02
212.54
Current Ratio 1.00
ENDP's Current Ratio is ranked lower than
88% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ENDP: 1.00 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.73 Max: 3.06
Current: 1
1
3.06
Quick Ratio 0.79
ENDP's Quick Ratio is ranked lower than
84% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ENDP: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.48 Max: 2.88
Current: 0.79
0.79
2.88
Days Inventory 117.59
ENDP's Days Inventory is ranked lower than
52% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. ENDP: 117.59 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 75.59  Med: 102.16 Max: 126.3
Current: 117.59
75.59
126.3
Days Sales Outstanding 111.11
ENDP's Days Sales Outstanding is ranked lower than
73% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. ENDP: 111.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.33  Med: 99.64 Max: 141.92
Current: 111.11
71.33
141.92
Days Payable 60.54
ENDP's Days Payable is ranked lower than
60% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. ENDP: 60.54 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 60.54  Med: 145.31 Max: 300.35
Current: 60.54
60.54
300.35

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.66
ENDP's Price/Projected FCF is ranked higher than
93% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. ENDP: 0.66 )
Ranked among companies with meaningful Price/Projected FCF only.
ENDP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.41  Med: 0.83 Max: 2.04
Current: 0.66
0.41
2.04
Price/Median PS Value 0.59
ENDP's Price/Median PS Value is ranked higher than
89% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. ENDP: 0.59 )
Ranked among companies with meaningful Price/Median PS Value only.
ENDP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.41  Med: 1.28 Max: 1.82
Current: 0.59
0.41
1.82
Price/Graham Number 0.72
ENDP's Price/Graham Number is ranked higher than
88% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. ENDP: 0.72 )
Ranked among companies with meaningful Price/Graham Number only.
ENDP' s Price/Graham Number Range Over the Past 10 Years
Min: 0.45  Med: 1.63 Max: 3.48
Current: 0.72
0.45
3.48
Earnings Yield (Greenblatt) (%) -7.40
ENDP's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. ENDP: -7.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENDP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 8.20 Max: 26.8
Current: -7.4
1.3
26.8
Forward Rate of Return (Yacktman) (%) 27.14
ENDP's Forward Rate of Return (Yacktman) (%) is ranked higher than
87% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. ENDP: 27.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENDP' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.3  Med: 30.25 Max: 63.3
Current: 27.14
3.3
63.3

More Statistics

Revenue(Mil) $3269
EPS $ -7.35
Beta0.95
Short Percentage of Float3.48%
52-Week Range $25.23 - 88.84
Shares Outstanding(Mil)222.20

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 4,316 4,665 4,862
EPS($) 5.74 6.56 7.23
EPS without NRI($) 5.74 6.56 7.23

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LSE:HIK, NYSE:MNK, SHSE:600196, BOM:524804, OSTO:MEDA A, TSE:4581 » details
Traded in other countries:ENL.Canada, EO7.Germany,
Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. Its current portfolio is associated with a set of therapeutic areas including, Allergy Immunotherapy, Central Precocious Puberty, Dermatology, Insomnia, Pain, Pelvic Health, Urology and Women's Health.
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Wallace Weitz Comments on Endo International Apr 22 2016 
Weitz Partners Value Fund 1st Quarter 2016 Commentary Apr 22 2016 
Weitz Value Funds' 1st Quarter 2016 Commentry Apr 22 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Steve Mandel Sells Allergan, DaVita During 4th Quarter Feb 29 2016 
Wallace Weitz Exits Stake in Alphabet, Cuts Oracle Feb 18 2016 
Wallace Weitz Comments on Endo International Jan 22 2016 
Wallace Weitz Offers Rare Intra-Quarter Portfolio Update Dec 21 2015 
Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Health Care Investor Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 

More From Other Websites
ETF’s with exposure to Endo International Plc : April 26, 2016 Apr 26 2016
Why Chesapeake, Whiting, Norfolk, Endo and Vivint Solar Are Among Today’s Big Gainers Apr 22 2016
Large investor is back for more in Endo Apr 22 2016
Endo to Announce First Quarter 2016 Financial Results on May 5, 2016 Apr 22 2016
Endo to Announce First Quarter 2016 Financial Results on May 5, 2016 Apr 22 2016
Endo to Announce First Quarter 2016 Financial Results on May 5, 2016 Apr 22 2016
Coverage initiated on Endo Intl by JMP Securities Apr 21 2016
The best entry in old tech stocks Apr 20 2016
Endo International: How Much Worse Can It Get? Apr 18 2016
The 52-Week Low Club for Tuesday Apr 12 2016
Five Healthcare Stocks that Disappointed Hedge Funds Apr 12 2016
Endo Pharmaceuticals: The Most Attractive Valeant-Like Company? Apr 12 2016
The 52-Week Low Club for Monday Apr 11 2016
Why These 5 Stocks Are Posting Big Moves Today Apr 11 2016
Endo International Tumbles as Insys Expects Weak Painkiller Sales Apr 11 2016
[$$] Four Buys After the Specialty-Pharma Selloff Apr 08 2016
Endo attracts long-term bullish position Apr 08 2016
ETF’s with exposure to Endo International Plc : April 8, 2016 Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK